CLINICAL TRIALS PROFILE FOR LAMISIL
✉ Email this page to a colleague
All Clinical Trials for LAMISIL
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00002394 ↗ | Safety and Effectiveness of Giving Lamisil to HIV-Positive Subjects With Thrush Who Have Not Responded to Fluconazole Treatment | Completed | Novartis | N/A | 1969-12-31 | The purpose of this study is to see if it is safe and effective to give Lamisil to HIV-positive patients with thrush (a fungal infection) that has not responded to fluconazole. |
| NCT00117767 ↗ | Terbinafine Compared to Griseofulvin in Children With Tinea Capitis | Completed | Novartis Pharmaceuticals | Phase 3 | 2004-06-01 | Tinea capitis is a dermatophyte infection of the scalp hair follicles, which occurs primarily in children. Hair loss, hair breakage, scaling, plus various degrees of erythema, pustules and pruritus are the primary clinical signs which can be associated with tinea capitis. The infection is caused by a relatively small group of dermatophytes in the genera Trichophyton and Microsporum. Terbinafine hydrochloride is a synthetic allylamine derivative antifungal agent. This study will evaluate the efficacy and safety of terbinafine in children with tinea capitis. |
| NCT00443820 ↗ | Efficacy Safety, and Tolerability of Topical Terbinafine in Patients With Mild to Moderate Toenail Fungus of the Big Toenail | Completed | Novartis Pharmaceuticals | Phase 3 | 2006-12-01 | This study is designed to assess the efficacy, safety and tolerability of a topical formulation of terbinafine solution applied daily in patients with toenail fungus. This trial will study patients with mild to moderate toenail fungus disease of the big toenail and their responses to two treatment durations, 24 or 48 weeks. |
| NCT00443898 ↗ | Efficacy, Safety, and Tolerability of Topical Terbinafine in Patients With Mild to Moderate Toenail Fungus of the Big Toenail | Completed | Novartis Pharmaceuticals | Phase 3 | 2006-12-01 | This study is designed to assess the efficacy, safety and tolerability of a topical formulation of terbinafine solution applied daily in patients with toenail fungus. This trial will study patients with mild to moderate toenail fungus disease of the big toenail and their responses to two treatment durations, 24 or 48 weeks. |
| NCT00459537 ↗ | Efficacy, Safety and Tolerability of Topical 10% Terbinafine Hydrogen Chloride Versus 5% Amorolfine Nail Lacquer in Patients With Mild to Moderate Toenail Onychomycosis | Completed | Novartis | Phase 3 | 2007-03-01 | This study will evaluate the efficacy, safety and tolerability of topical 10% terbinafine hydrogen chloride applied daily versus 5% amorolfine nail lacquer applied twice a week in patients with mild to moderate toenail onychomycosis, for a total treatment duration of 48 weeks. |
| NCT00602251 ↗ | Bioequivalency Study of Terbinafine Tablets Under Fed Conditions | Completed | Roxane Laboratories | N/A | 2004-03-01 | The objective of this study was the bioequivalence of a Roxane Laboratories' terbinafine tablets, 250 mg, to Lamisil® Tablets, 250 mg (Novartis Pharmaceutical Corporation.) under fed conditions using a single-dose, randomized, 2-treatment, 2-period, 2-sequence crossover design. |
| NCT00602342 ↗ | Bioequivalency Study of Terbinafine Tablets Under Fasting Conditions | Completed | Roxane Laboratories | N/A | 2004-03-01 | The objective of this study was the bioequivalence of a Roxane Laboratories' terbinafine tablets, 250 mg, to Lamisil® Tablets, 250 mg (Novartis Pharmaceutical Corporation.) under fasting conditions using a single-dose, randomized, 2-treatment, 2-period, 2-sequence crossover design. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for LAMISIL
Condition Name
Clinical Trial Locations for LAMISIL
Trials by Country
Clinical Trial Progress for LAMISIL
Clinical Trial Phase
Clinical Trial Sponsors for LAMISIL
Sponsor Name
